New Perspectives on Hypogonadism and Testosterone Replacement in Clinical Practice

Join 4 experts as they review the effect of hypogonadism and the role of testosterone replacement therapy in improving patient outcomes.

EXPERTS

Alvaro Morales, MD, FRCSC, FACS
Professor Emeritus, Department of Urology, School of Medicine, Queen’s University, Kingston, Ontario, Canada

Geoffrey Hackett, MD, FRCPI, MRCGP
Professor of Men’s Health, Department of Diabetes, University of Bedfordshire; Consultant in Urology, Good Hope Hospital, Sutton Coldfield, United Kingdom

Abraham Morgentaler, MD, FACS
Founder and Director, Men’s Health Boston; Associate Clinical Professor of Surgery (Urology), Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States

Michael Zitzmann, MD, PhD
Professor of Medicine, Endocrinologist, Andrologist, Diabetologist; Sexual Medicine (FECSM); Clinical Andrology, Centre for Reproductive Medicine and Andrology, Münster, Germany

To learn more about testosterone replacement, consult our online program at: www.medscape.org/collection/hypogonadism
New Perspectives on Hypogonadism and Testosterone Replacement in Clinical Practice

**Target Audience**
This activity is intended for a non-US audience, specifically primary care physicians, urologists, diabetologists/endocrinologists, cardiologists, and other healthcare professionals who need to be aware of symptoms or manage patients with hypogonadism.

**Goals**
The goals of this activity are to help participants identify patients with hypogonadism; provide an overview of the effect of the condition on quality of life and mortality; and review the role of testosterone replacement therapy in prostate, metabolic, and cardiovascular (CV) health.

**Learning Objectives**
Upon completion of this activity, participants will be able to:

- Identify the clinical effect of testosterone deficiency on men’s health, quality of life, and mortality
- Examine the latest clinical data on the interrelationships between hypogonadism and metabolic and CV risk factors, as well as between hypogonadism and prostate health
- Explain how to identify men at risk, diagnose hypogonadism, and how to treat and monitor patients, taking into account the latest clinical data and guidelines

**Accreditation Statement**
The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

**Commercial Support Acknowledgment**
This educational activity is supported by an independent educational grant from Bayer AG.

To learn more about testosterone replacement, consult our online program at: www.medscape.org/collection/hypogonadism